

Alpha Thalassemia Market - 2022-2031

<https://marketpublishers.com/r/A27EF7353DE6EN.html>

Date: March 2025

Pages: 220

Price: US\$ 2,999.00 (Single User License)

ID: A27EF7353DE6EN

Abstracts

The Alpha Thalassemia Market was valued at US\$ 1.1 billion in 2022 and is anticipated to reach US\$ 1.9 billion by 2031, at a CAGR of 0.074 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Alpha Thalassemia Market.

This report delivers a comprehensive overview of the Alpha Thalassemia Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Alpha Thalassemia Market. The Alpha Thalassemia Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

Alpha Thalassemia Market Scope:

By Type

Alpha Thalassemia Silent Carrier

Alpha Thalassemia Carrier

Hemoglobin H Disease

Alpha Thalassemia Major

By Treatment

Folic Acid Supplement

Iron Chelators

Blood Transfusion

Stem Cell Transplant

By End User

Hospitals

Ambulatory Surgical Centers

Others

Key Players

Agios Pharmaceuticals, Inc.

Actis

Novartis Pharmaceuticals Corporation

Global Calcium PVT LTD

CHIESI Farmaceutici S.p.A.

Taro Pharmaceutical Industries Ltd.

Amgen Inc.

Sun Pharmaceutical Industries Ltd.

FRESENIUS SE & Co. KGaA

Accelaron Pharma

Major Highlights

This report delivers a comprehensive overview of the Alpha Thalassemia Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Alpha Thalassemia Market. The Alpha Thalassemia Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the

latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by End User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Growing Advancements and Clinical Trials by Key Players
 - 4.1.1.2. Rising Alpha Thalassemia Disease Prevalence
 - 4.1.2. Restraints
 - 4.1.2.1. Unavailability of Proper Treatment for Alpha Thalassemia
 - 4.1.3. Opportunity
 - 4.1.3.1. Rising Collaboration by Key Players for Research and Development
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19

- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 7.1.2. Market Attractiveness Index, By Type
- 7.2. Alpha Thalassemia Silent Carrier *
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Alpha Thalassemia Carrier
- 7.4. Hemoglobin H Disease
- 7.5. Alpha Thalassemia Major

8. BY TREATMENT

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 8.1.2. Market Attractiveness Index, By Treatment
- 8.2. Folic Acid Supplement *
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Iron Chelators
 - 8.3.1. Deferoxamine (Desferal)
 - 8.3.2. Deferasirox
 - 8.3.2.1. Exjade
 - 8.3.2.2. Jadenu
 - 8.3.3. Deferiprone or L1 (Ferriprox)
- 8.4. Blood Transfusion
- 8.5. Stem Cell Transplant

9. BY END USER

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

9.1.2. Market Attractiveness Index, By End User

9.2. Hospitals *

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Ambulatory Surgical Centers

9.4. Others

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.6.1. Germany

10.3.6.2. U.K.

10.3.6.3. France

10.3.6.4. Spain

10.3.6.5. Italy

10.3.6.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

11. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY TYPE

12. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY TREATMENT

13. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY END USER

14. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY

14.1. Brazil

14.2. Argentina

14.3. Rest of South America

15. ASIA-PACIFIC

15.1. Introduction

15.2. Key Region-Specific Dynamics

15.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

15.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

15.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

15.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

15.6.1. China

15.6.2. India

15.6.3. Japan

15.6.4. Australia

15.6.5. Rest of Asia-Pacific

16. MIDDLE EAST AND AFRICA

16.1. Introduction

16.2. Key Region-Specific Dynamics

16.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

16.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

16.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

17. COMPETITIVE LANDSCAPE

- 17.1. Competitive Scenario
- 17.2. Market Positioning/Share Analysis
- 17.3. Mergers and Acquisitions Analysis

18. COMPANY PROFILES

- 18.1. Agios Pharmaceuticals, Inc. *
 - 18.1.1. Company Overview
 - 18.1.2. Product Portfolio and Description
 - 18.1.3. Financial Overview
 - 18.1.4. Key Developments
- 18.2. Actis
- 18.3. Novartis Pharmaceuticals Corporation
- 18.4. Global Calcium PVT LTD
- 18.5. CHIESI Farmaceutici S.p.A.
- 18.6. Taro Pharmaceutical Industries Ltd.
- 18.7. Amgen Inc.
- 18.8. Sun Pharmaceutical Industries Ltd.
- 18.9. FRESENIUS SE & Co. KGaA
- 18.10. Acceleron Pharma (*LIST NOT EXHAUSTIVE)

19. APPENDIX

- 19.1. About Us and Services
- 19.2. Contact Us

I would like to order

Product name: Alpha Thalassemia Market - 2022-2031

Product link: <https://marketpublishers.com/r/A27EF7353DE6EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A27EF7353DE6EN.html>